Pharmaceutical company Boehringer Ingelheim has begun patient enrolment in the Phase II clinical trial of BI 655064 for the treatment of lupus nephritis (LN).

Part of a collaboration between AbbVie and Boehringer Ingelheim, BI 655064 is a humanised mouse, anti-human monoclonal antibody being developed as an antagonist to CD40 present on B-cells in whole blood.

The double-blind, randomised, placebo-controlled, multi-centre Phase II trial will enrol a total of 120 patients in North America, Western and Eastern Europe, Asia and Australia.

Trial’s coordinating principal investigator Dr David Jayne said: “This trial is of great importance for patients with lupus nephritis, since it investigates a new and promising mechanism that has the potential to both improve kidney function and control of their lupus symptoms.”

"Our innovative trial is designed to include patients with active LN class III and IV and we are glad to be able to investigate a new potential treatment option for patients in urgent need."

The trial is designed to assess the efficacy and safety of three different sub-cutaneous doses of the drug over a period of 52 weeks in patients with active LN class III and IV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Boehringer Ingelheim immunology / CNS therapeutic area head Dr Jan Poth said: “Boehringer Ingelheim is dedicated to transforming lives of patients with immunological diseases.

“Our innovative trial is designed to include patients with active LN class III and IV and we are glad to be able to investigate a new potential treatment option for patients in urgent need.”

The trial’s primary endpoint is complete renal response at week 52, while other evaluations include overall systemic lupus erythematosus (SLE) symptoms, patient reported outcomes and fatigue.

Subjects participating in the trial will receive treatment with BI 655064 and standard-of-care therapy combination for one year, following which responders to therapy will be provided treatment for an additional two years.